GreenLight Biosciences announces $109 million financing

GreenLight Biosciences announces $109 million financing

GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, today announced a private placement of approximately $109 million.

"GreenLight's RNA platform has continued to prove its value as our research and development addresses a wide range of solutions to the world's challenges," said Andrey Zarur, CEO of GreenLight. "We are grateful for the support, conviction, and trust of our returning investors. We are also delighted to welcome new investors who have decided to join GreenLight in our mission to feed the world and keep it healthy.

"This funding enables our delivery of the first-ever externally applied RNA for crop protection. In coming months, we anticipate EPA approval and launch of Calantha™, our solution for control of the Colorado potato beetle. Later this year, we plan to make a regulatory submission of our solution targeting varroa mites, which are decimating honeybee colonies around the globe.

"In recent months, we have manufactured mRNA at scale with Samsung Biologics and launched partnerships to develop vaccines with the Vaccine Research Center at the National Institutes of Health and with The Serum Institute of India." GreenLight will be working to develop vaccines for COVID and shingles in the coming months.

"We are excited to support advances in GreenLight's mission, as demonstrated by recent partnerships with leading global institutions like Samsung, Serum Institute, and the National Institutes of Health," said Matt Walker, a Managing Director at S2G Ventures and member of GreenLight's Board of Directors. "This capital infusion from new and existing investors is not just a vote of confidence in GreenLight's team and technology platform, but also in its commercial progress and growing pipeline of opportunities in human and plant health."

The financing includes participation from new and existing institutional investors, including S2G Ventures, BNP Paribas Ecosystem Restoration Fund, Continental Grain Company, Cormorant Asset Management, the Cummings Foundation, Fall Line Capital, the FTX Foundation, Insud Pharma, Morningside Venture Investments, Rivas Capital, Sigmas Group, SymBiosis and certain directors and executive officers of GreenLight.

GreenLight intends to use the net proceeds from the financing to advance its development of research and commercial programs and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash and cash equivalents, is expected to be sufficient to fund operations through the first half of 2023. The Company continues to evaluate a range of opportunities to extend its cash runway, including management of program spending, platform licensing collaborations and potential financing activity.

GreenLight has agreed to sell approximately 27,844,383 shares of its common stock to a select group of institutional and accredited investors in a private placement, at a price per share of $3.92. Gross proceeds are expected to be approximately $109 million, before deducting offering expenses.

Credit Suisse and Baird served as joint placement agents for the private placement and Goodwin Procter served as legal counsel.

The securities described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. GreenLight has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in this private placement.

About GreenLight Biosciences

GreenLight Biosciences (Nasdaq: GRNA) aims to address some of the world's biggest problems by delivering on the full potential of RNA for human health and agriculture. Our RNA platform allows us to research, design, and manufacture for human, animal, and plant health. In human health, this includes messenger RNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The Company's platform is protected by numerous patents. GreenLight's human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to GreenLight's future finances, operations, or scientific developments. These forward-looking statements generally are identified by the words "aim to", "believe," "project," "target", "enables", "potential", "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result" and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including failure to receive regulatory approval, the evolution of the Covid-19 pandemic and therapies to address that pandemic, our ability to raise and productively deploy capital and the rate at which we can successfully bring products to market. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to, risks and uncertainties detailed from time to time in the Company's reports that it files with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 31, 2022 with the SEC, as well as its Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. For additional information on GreenLight and potential risks associated with investing, please see our public filings at https://www.sec.gov/edgar/browse/?CIK=1822691&owner=exclude.

Media Contact:
David Pesci
Head of Media Relations
GreenLight Biosciences
dpesci@greenlightbio.com
press@greenlightbio.com

Investor Contact:
investors@greenlightbio.com
https://investors.greenlightbio.com/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/25a156c2-b21f-4a73-a49f-c7cc84cadcd3


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GRNA
The Conversation (0)
GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Working toward clinical trial initiation for COVID vaccine candidate in 2023 Shingles vaccine candidate selection planned for 2023 in partnership with Serum Institute of India Calantha™, Colorado potato beetle solution, commercial launch planned for 2023, subject to regulatory approval Honeybee... Keep Reading...
GreenLight Biosciences to Participate in Upcoming Investor Conferences in November

GreenLight Biosciences to Participate in Upcoming Investor Conferences in November

GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the potential of RNA to address some of the world's toughest problems in human health and agriculture, today announced that Dr. Andrey Zarur, CEO, and Susan Keefe, CFO will participate in two upcoming... Keep Reading...
GreenLight Biosciences announces realignment to focus on near-term value drivers

GreenLight Biosciences announces realignment to focus on near-term value drivers

GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, today announced a realignment to focus on key near-term... Keep Reading...
GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA

GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA

GreenLight Biosciences and Queensland University of Technology (QUT) partner to create a solution for fall armyworm Fall armyworm is one of the most destructive insect pests on the planet, causing more than US$2 billion in annual crop loss worldwide The Australian government has been searching... Keep Reading...
GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

GreenLight raised $108.4 million in private placement led by S2G Ventures with strong participation from existing and new investors with cash expected to fund critical programs through the first half of 2023. GreenLight and Samsung Biologics completed their first commercial-scale engineering run... Keep Reading...
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News